An independent clinical and laboratory study of more than 3000 people treated with the drug natalizumab (Tysabri®) for multiple sclerosis (MS), Crohn’s disease, and rheumatoid arthritis has found no evidence of new cases of the often-fatal disorder called progressive multifocal leukoencephalopathy (PML). The laboratory component of the study was coordinated by the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH), working in conjunction with the NIH Clinical Center. Clinical and neuroradiological experts from other institutions also participated. Results of the study are published in the March 2, 2006, issue of the New England Journal of Medicine.
Natalizumab, an immune system-modifying drug, was approved by the U.S. Food and Drug Administration in November 2004 to treat relapsing-remitting MS. Studies have shown that it can substantially reduce the frequency of relapses in that disease. However, the drug was withdrawn from the market and from clinical trials in February 2005 after the manufacturer identified 2 cases of PML in MS patients who had received the drug. A person with Crohn's disease who had received natalizumab was also diagnosed with PML. The current study was conducted to determine whether other people treated with natalizumab were at risk of PML. Symptoms of PML include mental deterioration, problems with vision, speech, balance, and movement, and, in most cases, coma and death.
While the study did not find any evidence for new cases of PML, the researchers cannot say for certain that the patients who received natalizumab will not develop the disease in the future. The risk associated with longer-term treatment with natalizumab is also unknown. The results of this study are important not only for natalizumab, but also for similar drugs that are now in development.
Natalie Frazin or
Message posted by: Rashmi Nemade
Variants Associated with Pediatric Allergic Disorder
Mutations in PHF6 Found in T-Cell Leukemia
Genetic Risk Variant for Urinary Bladder Cancer
Antibody Has Therapeutic Effect on Mice with ALS
Regulating P53 Activity in Cancer Cells
Anti-RNA Therapy Counters Breast Cancer Spread
Mitochondrial DNA Diversity
The Power of RNA Sequencing
‘Pro-Ageing' Therapy for Cancer?
Niche Genetics Influence Leukaemia
Molecular Biology: Clinical Promise for RNA Interference
Chemoprevention Cocktail for Colon Cancer
more news ...